Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05828303
- Locations
- 🇪🇸
Local Institution - 2138, Madrid, M, Spain
🇺🇸Local Institution - 2102, Denver, Colorado, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05815680
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05789342
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741372
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 67
- Registration Number
- NCT05738291
- Locations
- 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands
Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 34
- Registration Number
- NCT05694221
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05598281
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 37
- Registration Number
- NCT05541471
- Locations
- 🇺🇸
Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT05526911
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.